



Personalized support for you and your patients

Amylyx Care Team (ACT)TM provides resources to help support adults with ALS throughout the RELYVRIOTM treatment process.



Rachel
Living with ALS

INDICATION

RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk in Patients With Enterohepatic Circulation Disorders, Pancreatic Disorders, or Intestinal Disorders
RELYVRIO contains taurursodiol, which is a bile acid. In patients with disorders that interfere with bile acid circulation, there may be an increased risk for worsening diarrhea, and patients should be monitored appropriately for this adverse reaction.

Please see additional Important Safety Information throughout and the full [Prescribing Information](#) for RELYVRIO.

 **relyvrio**TM
(sodium phenylbutyrate and
taurursodiol) for oral
suspension 3 g/1 g

Get your patients—and your practice—started with ACT™ today

Your patients receive personalized, one-on-one support from a dedicated ACT Care Coordinator



Ouriel
ACT Care Coordinator

How ACT works with you

ACT team members can help:

- Investigate insurance benefits
- Explain the prior authorization (PA) process and follow up on the status of submitted PAs
- Coordinate with specialty pharmacies to:
 - Support timely medication fulfillment
 - Deliver RELYVRIO™ (sodium phenylbutyrate and taurursodiol) to your patients' doorsteps

ACT team members can help your patients:

- Understand their insurance coverage
- Learn more about their ALS treatment
- Connect with other groups that support adults living with ALS
- Get started on RELYVRIO and receive continuous support while they are taking RELYVRIO

IMPORTANT SAFETY INFORMATION (CONTINUED)

WARNINGS AND PRECAUTIONS

Risk in Patients With Enterohepatic Circulation Disorders, Pancreatic Disorders, or Intestinal Disorders (continued)

Pancreatic insufficiency, intestinal malabsorption, or intestinal diseases that may alter the concentration of bile acids may also lead to decreased absorption of either of the components of RELYVRIO. Because different enterohepatic circulation, pancreatic, and intestinal disorders have varying degrees of severity, consider consulting with a specialist. Patients with disorders of enterohepatic circulation (eg, biliary infection, active cholecystitis), severe pancreatic disorders (eg, pancreatitis), and intestinal disorders that may alter concentrations of bile acids (eg, ileal resection, regional ileitis) were excluded from the study; therefore, there is no clinical experience in these conditions.

 **relyvrion™**
(sodium phenylbutyrate and taurursodiol) for oral suspension 3 g/1 g

Comprehensive financial assistance for eligible patients

We will help you and your patients navigate the access process and find affordable solutions through programs that include:

- **\$0 Co-Pay Program** for commercially insured patients*
- **Interim Access Program** that helps patients receive up to 2 months of RELYVRIO while they wait for approval from their insurance company
- **Patient Assistance Program**, which may be able to provide assistance for patients who do not have insurance or are unable to pay for treatment

*Out-of-pocket costs related to medication, appointments, evaluations, testing, or other related services are not covered by the RELYVRIO Co-Pay Program. The RELYVRIO Co-Pay Program is not available for prescriptions purchased under Medicare, Medicaid, TRICARE, or other federal- and state-funded programs. Amylyx reserves the right to amend or terminate the Program at any time without notice. Co-pay amounts after applying co-pay assistance may depend on the patient's insurance plan and may vary. The RELYVRIO Co-Pay Program is intended to help patients afford RELYVRIO.

Learn more about ACT™ support at AmylyxCareTeam.com

IMPORTANT SAFETY INFORMATION (continued)


Use in Patients Sensitive to High Sodium Intake

RELYVRIO has a high salt content. Each initial daily dosage of 1 packet contains 464 mg of sodium; each maintenance dosage of 2 packets daily contains 928 mg of sodium. In patients sensitive to salt intake (eg, those with heart failure, hypertension, or renal impairment), consider the amount of daily sodium intake in each dose of RELYVRIO and monitor appropriately.

Please see additional Important Safety Information throughout and the full [Prescribing Information](#) for RELYVRIO.



Sunshine
ACT Care Coordinator



Tyrone
Living with ALS



Enroll your patients in ACT™ today

3 simple steps to get your patients started

- 1** Complete and sign the RELYVRIO™ (sodium phenylbutyrate and taurursodiol) Enrollment Form provided or available at AmylyxCareTeam.com
- 2** Complete the prior authorization and/or letter of medical necessity, if needed
- 3** ACT will triage the prescription to one of our partner specialty pharmacies if the payer approves the request



IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

The most common adverse reactions (at least 15% and at least 5% greater than placebo) with RELYVRIO were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first 3 weeks of treatment.

You may report side effects to FDA at 1-800-FDA-1088.

For additional information about RELYVRIO, please see the full [Prescribing Information](#).



©2022 Amylyx Pharmaceuticals, Inc. All Rights Reserved. AMYLYX®, the AMYLYX® logo, RELYVRIO™, the RELYVRIO™ logo, AMYLYX CARE TEAM (ACT)™, and the AMYLYX CARE TEAM (ACT)™ logo are trademarks of Amylyx Pharmaceuticals, Inc. PM-00046 09/22

